Name:
FOURIER and Evolocumab
Description:
FOURIER and Evolocumab
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/6a03eb07-82d8-44ac-9408-be2e834eee71/thumbnails/6a03eb07-82d8-44ac-9408-be2e834eee71.jpeg?sv=2019-02-02&sr=c&sig=BeuLhXhbySJDgvf5psbfOlK9vE%2Bz8ar%2FslLSueyMiMM%3D&st=2024-12-21T14%3A39%3A24Z&se=2024-12-21T18%3A44%3A24Z&sp=r
Duration:
T00H03M46S
Embed URL:
https://stream.cadmore.media/player/6a03eb07-82d8-44ac-9408-be2e834eee71
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/6a03eb07-82d8-44ac-9408-be2e834eee71/18777605.mp3?sv=2019-02-02&sr=c&sig=A7Tuvlc1hSr1LuSdKg8VPqFGvaR0GgP3eVLgFHrj1Ow%3D&st=2024-12-21T14%3A39%3A24Z&se=2024-12-21T16%3A44%3A24Z&sp=r
Upload Date:
2022-02-28T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
>> Practice Impact Extra podcasts are derived from Hurst's, The Heart Board Review, and other online resources available only through accesscardiology.com. [ Music ] >> We've all come to know the effects in -- the dramatic effects on LDL lowering with the PCSK9's, and I wanted to really present a study that I think gives us more information on outcomes. [ Music ] Achieving LDL guidelines in cardiovascular disease, even with maximum statin treatment, has been a challenge.
The development of monoclonal antibody, particularly PCSK9 inhibitor, was allowed to dramatically lower LDL cholesterol and cardiovascular events. Are there any new practice impact analysis that can add further knowledge to the prior seen benefit? As you remember, the FOURIER Trial was published in March 2019. It randomized 27,000 patients to PCSK9 and to Evolocumab and to placebo.
The results revealed reduced major vascular events over a two-year period. I want to review today a prespecified analysis of the FOURNIER Trial to evaluate the effect on the inhibitor on different types and sizes of myocardial infarction in a patient with stable atherosclerosis who are also receiving statin therapy. In JAMA Cardiology in April of 2020, they published the results of this prespecified analysis of the FOURNIER Trial.
Once again, the FOURNIER Trial randomized 27,000 patients, of whom 1,100 patients experienced a total of 1,200, almost 1,300 myocardial infarctions. Most of these were secondary to atherothrombosis. The majority MI's had troponin levels greater than 10 times the upper limit of normal. So what were the results? Evolocumab reduced the risk of first myocardial infarction, a significant 27% compared to placebo.
There was a highly significant benefit regardless of the size of the MI with a 34% reduction in myocardial infarctions. In patients who had a troponin level 10 times the upper limit of normal, they noticed that there was a 36% reduction in the risk of STEMI. So what relevance does this brief specific trial provide? LDL lowering with Evolocumab was highly effective in reducing the risk of myocardial infarction across multiple subtypes of MI related to plaque rupture, small or larger MI's, including STEMI and non-STEMI.
This trial, this prespecified trial, supports the prior-known benefit of LDL lowering and underscores the reduction of clinically meaningful events. I want to thank you for joining me and see you next time on Practice Impact Extra. >> We hope you enjoyed this podcast from McGraw-Hill. Subscribers to AccessCardiology have instant access to over 25,000 pages of rich medical content, receive medical updates from trusted experts, and have access to other special features.
To subscribe or learn more, please visit accesscardiology.com.
